Aevi Genomic Medicine Shares Outstanding 2012-2018 | GNMX

Aevi Genomic Medicine shares outstanding history from 2012 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Aevi Genomic Medicine shares outstanding for the quarter ending June 30, 2018 were 0.059B, a 59.9% increase year-over-year.
  • Aevi Genomic Medicine 2017 shares outstanding were 0.042B, a 18.53% increase from 2016.
  • Aevi Genomic Medicine 2016 shares outstanding were 0.035B, a 30.98% increase from 2015.
  • Aevi Genomic Medicine 2015 shares outstanding were 0.027B, a 39.14% increase from 2014.
Aevi Genomic Medicine Annual Shares Outstanding
(Millions of Shares)
2017 42
2016 35
2015 27
2014 19
2013 18
2012 11
2011 8
Aevi Genomic Medicine Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 59
Q1 2018 59
Q4 2017 42
Q3 2017 37
Q2 2017 37
Q1 2017 37
Q4 2016 35
Q3 2016 37
Q2 2016 33
Q1 2016 33
Q4 2015 27
Q3 2015 25
Q2 2015 25
Q1 2015 25
Q4 2014 19
Q3 2014 19
Q2 2014 19
Q1 2014 19
Q4 2013 18
Q3 2013 18
Q2 2013 18
Q1 2013 16
Q4 2012 11
Q3 2012 12
Q2 2012 10
Q1 2012 10
Q4 2011 8
Q3 2011 10
Q2 2011 9
Q1 2011 5
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.074B $0.000B
Aevi Genomic Medicine Inc. is focused on genomic medicine. The Company focuses on translating genetic discoveries into novel therapies. Its product candidates include AEVI-001 and AEVI-002 which are in clinical trial stage. Aevi Genomic Medicine Inc., formerly known as Medgenics Inc., is based in WAYNE, United States.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $64.335B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Mylan (MYL) United Kingdom $16.606B 7.06
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Supernus Pharmaceuticals (SUPN) United States $2.517B 26.93
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.485B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Corium (CORI) United States $0.454B 0.00
Teligent (TLGT) United States $0.185B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Versartis (ARAV) United States $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00